Koninklijke Philips N.V. Q3 2026 Earnings Recap

Philips shares rose 12.6% after earnings, as investors rewarded a 70-basis-point adjusted EBITA margin increase to 13%, ahead of management’s expectations, alongside 8% order intake growth. The full-year outlook was reiterated; sales growth was more modest at approximately 3%, with Diagnosis & Treatment broadly flat and Connected Care orders down mid-single digit.

Key Takeaways

• Comparable sales grew approximately 3% in Q3, led by Personal Health and Connected Care; Personal Health grew 8%.
• Order intake increased 8%, including nearly 20% growth in Diagnosis & Treatment. Equipment order intake also grew 8%, and the equipment order book rose sequentially and year on year.
• Adjusted EBITA margin expanded 70 basis points to 13%; free cash flow was an inflow of EUR 384 million.
• Connected Care order intake declined mid-single digit against a high prior-year comparison, with some major orders shifting into Q4. Diagnosis & Treatment sales were broadly flat, reflecting ultrasound shipment timing and lower sales in China.
• Philips recorded a EUR 288 million provision related to the agreement in principle with the U.S. Department of Justice concerning Respironics. The company reiterated its full-year outlook.